EHA 2025 | An indirect comparison of BPD versus DVD in RRMM: an analysis of the DREAMM-7 and DREAMM-8 trials

In the DREAMM-7 and 8 studies, the experimental arm contains the belamaf in combination with either bortezomib or pomalidomide. And the experimental arm is compared to the control arm which is daratumumab bortezomib dexamethasone or pomalidomide bortezomib dexamethasone. So it was possible in an identical setting to compare the experimental arm of the DREAMM-8 study which is belamaf in combination with POM and DEX versus the control arm of DREAMM-7 study which is daratumumab, bortezomib and DEX. That’s how this current analysis was planned and 96 and 99 patients in both studies were eligible for comparison in this matched analysis that excludes daratumumab exposure and refractory and used to be able to make a fair comparison. And after the analysis it was possible to see that the PFS advantage for belamaf in combination with pomalidomide dexamethasone is still valid against daratumumab, bortezomib, dexamethasone, and the hazard ratio is 0.41. The PFS advantage for belamaf combination with pomalidomide dexamethasone, the PFS median is not reached and versus dara-VD arm being 11 months. Overall response rates in both arms were similar. However, the MRD rate being 23% in the belamaf-POM-DEX versus only 5% in the dara-VD arm. And the duration of response is also significantly in favor of the belamaf-pomalidomide-dexamethasone. So for patients who are relapsing after one or more lines of therapy, this combination of an ADC in combination with pomalidomide dexamethasone is a valid option and that can be preferred against daratumumab in combination with bortezomib and dexamethasone.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.